Targeting DNA Repair Pathways: Current and Future Implications of PARP Inhibitors
This bundle includes 3 recorded webinars of the PARPi live broadcast. Each webinar includes a pre-test, the recorded presentation, handout, the audience QA, and a post test. Continuing Education Credit is also available for all three of these talks.
Ryan Jensen, PhD
Peter Park, PhD
Katherine Nathanson, MD
Payal Shah, MD
Description: Many recent studies have highlighted the importance of DNA repair pathways and the significance of PARP inhibitors. Using Homologous Recombination Deficiency (HRD) testing, ovarian and breast cancers are currently the most well studied for the subsequent use of PARP inhibitor (PARPi) therapy. More information is emerging regarding HRD testing in prostate and pancreatic cancers, and clinical trials for PARP inhibitor therapy applications in these diseases are underway as well. AMP subject matter experts organized known scientific underpinnings and the most current research and clinical information into an up-to-date and useful three-part webcast series titled, “Targeting DNA Repair Pathways: Current and Future Implications of PARP Inhibitors”. This series will cover:
- The mechanism of action of PARP inhibitors and the science of Homologous Recombination Deficiency (HRD) testing,
- Laboratory considerations (from sample acquisition to result reporting) for HRD testing, and
- Clinical considerations for testing and treatment and the need for genetic counseling.
Duration: 3 hours
Level of Instruction: Basic
CME/CMLE credit: 3.00 hours
SAM credit: 3.00 hours
Last Day to Claim Credit: December 31, 2021
Target Audience: clinical laboratory professionals, oncologists, and genetic counselors as well as many other healthcare professionals engaged in the diagnosis, treatment, and care of cancer patients.
For more information about this series, go here.
Supported by educational grants provided by AstraZeneca and Merck
Last day to purchase bundle and claim credit: December 31, 2021
SAMS Satisfactory Completion
Learners must pass the MOC post-test with a score of 75% or higher and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Association for Molecular Pathology. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 3.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Amedco and joint provider-ship of the American Society for Clinical Pathology (ASCP) and the Association for Molecular Pathology (AMP). ASCP CMLE credit hours are acceptable for the ASCP Board of Certification Maintenance Program (CMP)
American Board of Pathology Self-Assessment Credit
This course is valid for up to 3.0 of SA-CME Self-Assessment credits (SAMs). Learners should self-submit these credits to their boards.
* You may not submit SAMs and CME/CMLE credit for the same content.